See the DrugPatentWatch profile for Wainua
The Wainua autoinjector is a device used for the subcutaneous administration of Wainua (epligramab-gxby), a medication indicated for adults with symptomatic obstructive coronary artery disease (CAD) [1]. Epligramab-gxby is a novel, fully human monoclonal antibody targeting ANGPTL3 [1][2].
How does Wainua work?
Wainua targets and inhibits angiopoietin-like protein 3 (ANGPTL3) [1][2]. ANGPTL3 is a liver-produced protein that plays a role in regulating lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL) [2]. By inhibiting ANGPTL3, Wainua reduces the activity of LPL and EL, leading to decreased triglyceride levels and increased HDL cholesterol levels [2].
What is Wainua prescribed for?
Wainua is prescribed for adults with symptomatic obstructive coronary artery disease (CAD) [1]. It is intended to be used in conjunction with maximally tolerated statin therapy and other lipid-lowering treatments in patients who have undergone surgical or percutaneous revascularization or who have other clinically evident cardiovascular disease [1].
What are the potential side effects of Wainua?
The most common side effects reported in clinical trials for Wainua include injection site reactions, nasopharyngitis (common cold symptoms), and fatigue [1].
When does the patent for Wainua expire?
Information regarding the specific patent expiration dates for Wainua is not readily available in the provided text. Patent protection is a complex area that can involve multiple patents covering different aspects of a drug and its delivery devices. For detailed patent information, resources like DrugPatentWatch.com can be consulted [3].
How is Wainua administered?
Wainua is administered via subcutaneous injection using an autoinjector [1]. The autoinjector is designed for self-administration by patients [1].
What is the difference between Wainua and other lipid-lowering therapies?
Wainua represents a novel approach to lipid management by targeting ANGPTL3, a protein upstream of many other lipid-regulating pathways [2]. Unlike statins, which primarily target HMG-CoA reductase, or PCSK9 inhibitors, which target the PCSK9 enzyme, Wainua acts by inhibiting ANGPTL3. This mechanism leads to a reduction in triglycerides and an increase in HDL cholesterol [2]. Its indication in symptomatic obstructive CAD signifies its role in managing cardiovascular risk in specific patient populations [1].
Who manufactures Wainua?
Wainua is manufactured by Amarin Corporation plc [1].